Open AccessImpact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine
Author(s) -
Jerry Jeffrey,
Marty St. Clair,
Ping Wang,
Chunfu Wang,
Zhufang Li,
Jagadish Beloor,
Christine L. Talarico,
Robert A. Fridell,
Mark Krystal,
Carl White,
Sandy Griffith,
Ronald D’Amico,
Kimberly Y. Smith,
Veerle Van Eygen,
Johan Vingerhoets,
Kati Vandermeulen,
William Spreen,
Jan van Lunzen
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01702-21
Subject(s) - rilpivirine , dolutegravir , abacavir , integrase , integrase inhibitor , virology , biology , lamivudine , potency , human immunodeficiency virus (hiv) , emtricitabine , elvitegravir , pharmacology , medicine , viral load , in vitro , antiretroviral therapy , virus , genetics , hepatitis b virus
The FLAIR study demonstrated noninferiority of monthly long-acting cabotegravir + rilpivirine versus daily oral dolutegravir/abacavir/lamivudine for maintaining virologic suppression. Three participants who received long-acting therapy had confirmed virologic failure (CVF) at Week 48, and all had HIV-1 that was originally classified as subtype A1 and contained the baseline integrase polymorphism L74I; updated classification algorithms reclassified all 3 as HIV-1 subtype A6.